

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma	Version No: 1.1	Effective Date: 05/15/2023
	Short Title- A092107	Replaces: 1.0	Page 1 of 11

CORRELATIVE SCIENCE PROCEDURE MANUAL

1. Purpose

This document describes the procedures required for the collection, shipping, and processing of biospecimens from all patients enrolled or registered on A092107. This document also describes the procedures that will be followed subsequent to the receipt of biospecimens by the Alliance Biorepository (i.e. Siteman Cancer Center Tissue Procurement Core at Washington University), prior to their use for protocol-specified and future, unspecified correlative science research studies. This document should be used by staff involved with any aspect of the A092107 biospecimen collection, processing, and submission, including staff at satellite institutions.

2. Scope

This document applies to all biospecimens collected specifically for A092107 only. Please refer to the trial protocol-specific language for additional details regarding eligibility, participant enrollment, data submission, and specific procurement procedures. **Please ensure that you are reading the most updated version of this document. This document may experience minor updates, revisions, and clarifications independent of a formal protocol amendment. The most recent version of this document may be found on the Alliance website and CTSU.**

3. Definitions

Term	Definition
ABWUSTL	Alliance Biorepository at Washington University in St. Louis
FFPE	Formalin fixed, paraffin embedded

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma	Version No: 1.1	Effective Date: 05/15/2023
	Short Title- A092107	Replaces: 1.0	Page 2 of 11

4. Contact Information

Protocol-related questions may be directed as follows:	
Questions	Contact (via email)
Questions regarding patient eligibility, treatment, and dose modification:	Study Chair: Steven Robinson, MD Robinson.Steven@mayo.edu Nursing Contact: Lisa Kottschade, APRN, MSN, CNP kottschade.lisa@mayo.edu Protocol Coordinator: Beth Smith beth10@bsd.uchicago.edu (where applicable) Data Manager: Brandon Bright Bright.Brandon@mayo.edu
Questions related to data submission, RAVE or patient follow-up:	Data Manager: Brandon Bright Bright.Brandon@mayo.edu
Questions regarding the protocol document and model informed consent:	Protocol Coordinator: Beth Smith beth10@bsd.uchicago.edu
Questions related to IRB review:	Alliance Regulatory Inbox regulatory@allianceNCTN.org
Questions regarding CTEP-AERS reporting:	Alliance Pharmacovigilance Inbox pharmacovigilance@alliancencn.org
Questions regarding specimens/specimen submissions:	Alliance Biorepository at Washington University (WUSTL), alliance@email.wustl.edu
Questions regarding drug supply:	McKesson Clinical Research Services: 800-693-4903

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead- In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma Short Title- A092107	Version No: 1.1	Effective Date: 05/15/2023
		Replaces: 1.0	Page 3 of 11

Questions regarding drug administration:	Pharmacy Contact: Brian P. Strittmatter, PharmD, MS bstrittm@wakehealth.edu
--	---

- 4.1** For information on using the BioMS system, please refer to the ‘Help’ links on the BioMS webpage to access the online user manual, FAQs, and training videos. To report technical problems, such as login issues or application errors, please contact: 1-855-55-BIOMS or bioms@alliancenctn.org. For assistance in using the application or questions or problems related to specific specimen logging, please contact: 1-855-55-BIOMS or bioms@alliancenctn.org.
- 4.2** For all other questions regarding biospecimen procurement and shipping procedures, please contact the Alliance Biorepository Program Manager: 1-314-747-4402 or alliance@email.wustl.edu.

5. Site Preparation

- 5.1** Please refer to A092107 protocol document for any specific requirements related to patient enrollment, registration, and regulatory compliance.
- 5.2** Please ensure that you have appropriate log on credentials and can successfully access the BioMS application. The BioMS application is used for logging the collection and shipment of biospecimens to the Alliance Biorepository at Washington University. For training and assistance in using the application or questions or problems related to specific specimen logging, please contact: 1-855-55-BIOMS or bioms@alliancenctn.org.

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma Short Title- A092107	Version No: 1.1	Effective Date: 05/15/2023
		Replaces: 1.0	Page 4 of 11

6. Collection Schema

The following biospecimens are to be collected at each of the time points. Please refer to individual collection kit instructions, biospecimen collection and processing methods, and specific shipping procedures below.

Time Point	Kit (Y/N)	Biospecimen	Quantity	Collection / Processing Method	Shipping	Receiving Lab	Notes
For Patients Registered to A092107-ST1							
Within 60 days of registration	N	Fixed tissue block	1	Fixed tissue block (9.2)	Ambient	ABWUSTL	1, 2
Within 60 days of registration	N	Unstained slides	20 x 5 micron unstained slides	Fixed tissue slides (9.3)	Ambient	ABWUSTL	1, 2
For Patients Registered to A092107 Biobanking							
Prior to C1D1	N	Whole blood (EDTA tube)	2 x 10 ml	Whole blood-EDTA tube (10.1)	Ambient	ABWUSTL	1, 3, 4
C2D1 (Prior to treatment)	N	Whole blood (EDTA tube)	2 x 10 ml	Whole blood-EDTA tube (10.1)	Ambient	ABWUSTL	1, 3, 4
Progression/ End of Treatment	N	Whole blood (EDTA tube)	2 x 10 ml	Whole blood-EDTA tube (10.1)	Ambient	ABWUSTL	1, 4

Notes:

- Collection is optional for patients but requires all sites offer to patients to consent. Please see protocol-specific consent documents.
- A representative, archived diagnostic tumor tissue block from biopsy or surgery should be submitted, if available. If entire tissue block cannot be submitted, up to twenty (5 um) serial tissue sections will be accepted as an alternative. If tissue is limited, please submit as many tissue sections as possible. **BLOCK SUBMISSION IS STRONGLY PREFERRED.**
- All labs may be obtained within ≤ 72 hours prior to treatment.
- Whole blood sample in EDTA tubes will be collected for PBMC isolation and cryopreservation at the Biorepository.

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma	Version No: 1.1	Effective Date: 05/15/2023
	Short Title- A092107	Replaces: 1.0	Page 5 of 11

7. Biospecimen Collection Kits

7.1 Blood Specimens

7.1.1 There are no “kits” provided for submission of blood specimens for this study. Sites are responsible for acquiring materials for collection and shipping of biospecimens to the Biorepository.

7.2 Tissue Specimens

7.2.1 There is no independent “kit” for submission of paraffin blocks or unstained slides.

7.2.2 Paraffin blocks and unstained slides should be packaged to avoid breakage using a padded envelope or, preferably, a small Styrofoam container.

7.2.3 During warm weather months, paraffin blocks and unstained slides should be shipped in an insulated container that contains a refrigerant pack, to avoid heat > 25 degrees C (77 degrees F) that may melt paraffin and damage the tissue specimens.

7.2.4 Please see **Section 11 – Biospecimen Shipping** for specific instructions on shipping.

8. Biospecimen Labeling and Tracking

8.1 All research biospecimens (vacutainer tubes and tissue bags) MUST be labeled with the Alliance patient ID number, patient initials (Last, First, Middle), the date and time (if applicable) of collection and specimen type.

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma	Version No: 1.1	Effective Date: 05/15/2023
	Short Title- A092107	Replaces: 1.0	Page 6 of 11

- 8.2** Surgical pathology tissue blocks should not be labeled in any manner. The institutional surgical pathology number (e.g. “S16-1234”) and the individual block identifier (e.g. “A3”) should be readable on the block. If slides are being submitted instead of the block, each unstained slide should be labeled with the Alliance patient ID number, institutional surgical pathology number, and the block identifier. Provide a **de-identified copy of the surgical pathology report**, labeled with the Alliance patient ID number, corresponding to the block or unstained slides submitted. Please ensure the institutional surgical pathology number and block ID are maintained on the surgical pathology report. See **section 9** for additional details.
- 8.3** Label all containers and vials with an indelible, solvent-resistant marker when they are at ambient temperature.
- 8.4** Do not affix any labels to vials, slides or tubes. Label the collection containers directly with the marking pen.
- 8.5** All biospecimens that are collected and sent to the Alliance Biorepository must be **logged and tracked in BioMS**. The BioMS system is a web-based application that tracks the collection and shipping of biospecimens. Once individual biospecimens are logged and ‘shipped’ in the BioMS system, a packing manifest will be created by the system. This manifest must be printed out and must accompany all biospecimen shipments. To become familiar with the BioMS system and for further information about training, access, and use, please contact the BioMS Help desk at: 1-855-55-BIOMS or bioms@alliancencntr.org.
- 8.6** In the event that BioMS cannot be accessed, please complete a BioMS Specimen Log and Shipping Manifest form which can be found here- <http://tinyurl.com/alliance-bioms-contingency>.

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma	Version No: 1.1	Effective Date: 05/15/2023
	Short Title- A092107	Replaces: 1.0	Page 7 of 11

9. Tissue Collection

9.1 Overview.

- 9.1.1** Please refer to protocol-specific instructions for procedures related to actual tissue procurement from individual participants. The method for research tissue procurement (needle core biopsy, sampling of surgically resected tumor) is dependent upon the disease site and the individual patient.
- 9.1.2** When procuring tissue biospecimens by any method, when possible, avoid tissue that is grossly necrotic, hemorrhagic, fatty, or fibrous. If in doubt, briefly (1 min or less) place the tissue segment in a sterile specimen cup containing physiologic (normal) saline to rinse the tissue. Necrotic, hemorrhagic, and fatty tissue will generally dissolve or float on the surface while tumor and parenchymal tissue will remain intact and sink to the bottom of the cup.
- 9.1.3** **During warm weather months, paraffin blocks and slides should be shipped in an insulated container that contains a refrigerant pack, to avoid heat > 25 degrees C (77degrees F) that may melt paraffin and damage the tissue specimens.**


9.2 Fixed Tissue Block

- 9.2.1** For patients who consented to sub-study A092107-ST1, a representative diagnostic block with adequate tumor should be submitted, if applicable.
- 9.2.2** Any clinical surgical pathology block that is submitted for research studies will not be exhausted or rendered unsuitable for future diagnostic use. Any clinical surgical pathology block that is submitted will be returned within ten working days of written request, when needed for clinical management or clinical trial enrollment for a specific patient. Otherwise, all blocks will be returned to the submitting institution when the trial and correlative science study endpoints have been met.
- 9.2.3** **Include a copy of a de-identified pathology report with block submission.**

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma	Version No: 1.1	Effective Date: 05/15/2023
	Short Title- A092107	Replaces: 1.0	Page 8 of 11

9.3 Fixed Tissue Slides

- 9.3.1 In cases where an institution is unwilling or unable to submit the requested tissue block, twenty (5 micron) unstained slides cut from a single diagnostic tumor tissue block may be submitted as an alternative. Block submission is highly preferred.
- 9.3.2 Serial tissue sections should be cut fresh from the appropriate formalin fixed, paraffin embedded tissue block.
- 9.3.3 Cut sections at 5 micron thickness onto positively charged glass slides. See figure below for proper mounting and labeling.



- 9.3.4 Do not label slides with adhesive labels. Write or print information on the textured surface of the slide with indelible, solvent-resistant ink.
- 9.3.5 Air dry slides for 12-24 hours prior to shipping. Do not oven dry slides.

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma	Version No: 1.1	Effective Date: 05/15/2023
	Short Title- A092107	Replaces: 1.0	Page 9 of 11

9.3.6 Use slide mailers or a slide box to ship slides. Slides should not be touching each other. Ensure that slides from only one patient are placed in one slide mailer.

9.3.7 Include a copy of a **de-identified** pathology report with all tissue submissions.

10. Blood Collection Methods

10.1 Whole blood (EDTA- no processing)

10.1.1 Collect 10 ml of whole blood by standard venous phlebotomy technique into each of the EDTA tubes. Invert tubes 10 times.

10.1.2 Store EDTA tubes with whole blood at 4 degrees Celsius (i.e. refrigerated) until shipping. Do not freeze the tubes. **Please collect blood on Monday through Thursday only. The tubes must be received at the Biorepository within 24 hours of collection.** Ensure that the EDTA tubes are shipped at ambient temperature to avoid freezing. **During warm weather months (i.e. June – August), a refrigerated pack (not frozen) should be included in the shipment to maintain ambient temperature. When shipping during other months of the year, a room temperature pack should be included in the shipment.**

11. Biospecimen Shipping

11.1 Overview

11.1.1 Place the original, completed copy of the BioMS packing manifest in the shipment. If sending tissue, include a copy of the de-identified surgical pathology report, labeled with the patient study number. Do not send specimens without a completed BioMS Packing Manifest or substitute “BioMS Downtime Form.” Biospecimens cannot be accepted without this completed form.

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma	Version No: 1.1	Effective Date: 05/15/2023
	Short Title- A092107	Replaces: 1.0	Page 10 of 11

11.1.2 All biospecimens should be shipped within the timeframes indicated above in **sections 9 and 10**. If collected biospecimens cannot be shipped within the specified timeframe (e.g. Friday – Saturday or Holiday collections), please contact the Alliance Biorepository Program Manager: 1-314-747-4402 or alliance@email.wustl.edu for further instructions, at least 24 hours prior to anticipated collection.

11.1.3 **Do not ship on Friday, Saturday, Sunday or the day before a nationally recognized holiday.**

11.2 Shipping to ABWUSTL

11.2.1 Ship container for PRIORITY OVERNIGHT DELIVERY according to IATA guidelines and standard institutional policies and using the preferred vendor.

Ship to:

**Alliance Biorepository
c/o Siteman Cancer Center Tissue Procurement Core
Washington Univ. School of Medicine
425 S. Euclid Ave.
Room 5120
St. Louis, MO
63110-1005
Phone: 314-454-7615**

12. ABWUSTL Biospecimen Receipt and Quality Assurance Measures

12.1 Upon receipt, all biospecimens will be accessioned into the TPC informatics system, OpenSpecimen.

12.2 All biospecimens will be logged, associated, and tracked by the unique patient biopsy control number.

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY	CORRELATIVE SCIENCE PROCEDURE MANUAL A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma	Version No: 1.1	Effective Date: 05/15/2023
	Short Title- A092107	Replaces: 1.0	Page 11 of 11

- 12.3** Each individual biospecimen will receive and be physically labeled with a unique biospecimen identifier, associated with the biopsy control number in the TPC informatics system.
- 12.4** Upon receipt, all physical biospecimens received will be reconciled with what is recorded on the BioMS packing manifest. Any discrepancies noted will be communicated to the Program Manager who will contact the submitting site for reconciliation.
- 12.5** Upon receipt, any biospecimen received that is not in appropriate physical condition (broken vials, frozen samples that are thawed, ambient samples that are frozen) will be reported to the Program Manager, who will contact the submitting site for reconciliation.
- 12.6** Frozen aliquoted biofluids will be stored under liquid nitrogen vapor.
- 12.7** All biospecimens will remain in storage until additional processing or review is requested in writing by the appropriate protocol PI.

13. Document History

Version	Description and Justification of Change	Author	Effective Date
1.1	“Within 30 days of registration” timepoint changed to “Within 60 days of registration”, added contact info, removed C1D28 collection timepoint, added warm weather shipping instructions for tissue	KAL	05/12/2023
1.0	New	AAW	01/04/2023